QIAGEN EBITDA Margin 2010-2023 | QGEN
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for QIAGEN (QGEN) over the last 10 years. The current EBITDA margin for QIAGEN as of March 31, 2023 is .
| QIAGEN EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2023-03-31 |
$2.00B |
$0.66B |
33.12% |
| 2022-12-31 |
$2.14B |
$0.77B |
36.09% |
| 2022-09-30 |
$2.23B |
$0.84B |
37.60% |
| 2022-06-30 |
$2.26B |
$0.87B |
38.66% |
| 2022-03-31 |
$2.31B |
$0.92B |
39.66% |
| 2021-12-31 |
$2.25B |
$0.88B |
38.92% |
| 2021-09-30 |
$2.24B |
$0.87B |
38.75% |
| 2021-06-30 |
$2.19B |
$0.78B |
35.72% |
| 2021-03-31 |
$2.07B |
$0.74B |
35.64% |
| 2020-12-31 |
$1.87B |
$0.64B |
33.96% |
| 2020-09-30 |
$1.71B |
$0.55B |
32.36% |
| 2020-06-30 |
$1.61B |
$0.31B |
18.99% |
| 2020-03-31 |
$1.55B |
$0.26B |
16.77% |
| 2019-12-31 |
$1.53B |
$0.25B |
16.18% |
| 2019-09-30 |
$1.52B |
$0.25B |
16.61% |
| 2019-06-30 |
$1.51B |
$0.53B |
34.85% |
| 2019-03-31 |
$1.51B |
$0.51B |
33.97% |
| 2018-12-31 |
$1.50B |
$0.51B |
33.82% |
| 2018-09-30 |
$1.50B |
$0.47B |
31.08% |
| 2018-06-30 |
$1.48B |
$0.45B |
30.57% |
| 2018-03-31 |
$1.45B |
$0.42B |
28.89% |
| 2017-12-31 |
$1.42B |
$0.40B |
27.86% |
| 2017-09-30 |
$1.39B |
$0.36B |
25.65% |
| 2017-06-30 |
$1.36B |
$0.34B |
25.02% |
| 2017-03-31 |
$1.35B |
$0.34B |
25.52% |
| 2016-12-31 |
$1.34B |
$0.33B |
24.81% |
| 2016-09-30 |
$1.32B |
$0.38B |
28.86% |
| 2016-06-30 |
$1.30B |
$0.38B |
28.94% |
| 2016-03-31 |
$1.28B |
$0.38B |
29.43% |
| 2015-12-31 |
$1.28B |
$0.39B |
30.52% |
| 2015-09-30 |
$1.29B |
$0.36B |
28.17% |
| 2015-06-30 |
$1.31B |
$0.37B |
27.80% |
| 2015-03-31 |
$1.33B |
$0.37B |
28.15% |
| 2014-12-31 |
$1.34B |
$0.38B |
28.13% |
| 2014-09-30 |
$1.35B |
$0.38B |
28.10% |
| 2014-06-30 |
$1.33B |
$0.36B |
27.12% |
| 2014-03-31 |
$1.32B |
$0.28B |
21.22% |
| 2013-12-31 |
$1.30B |
$0.26B |
20.12% |
| 2013-09-30 |
$1.29B |
$0.28B |
21.51% |
| 2013-06-30 |
$1.27B |
$0.28B |
22.13% |
| 2013-03-31 |
$1.26B |
$0.36B |
28.53% |
| 2012-12-31 |
$1.25B |
$0.37B |
29.35% |
| 2012-09-30 |
$1.24B |
$0.29B |
23.53% |
| 2012-06-30 |
$1.23B |
$0.28B |
22.84% |
| 2012-03-31 |
$1.20B |
$0.27B |
22.56% |
| 2011-12-31 |
$1.17B |
$0.27B |
22.75% |
| 2011-09-30 |
$1.12B |
$0.33B |
29.26% |
| 2011-06-30 |
$1.11B |
$0.30B |
27.22% |
| 2011-03-31 |
$1.09B |
$0.26B |
23.83% |
| 2010-12-31 |
$1.09B |
$0.26B |
24.01% |
| 2010-09-30 |
$1.09B |
$0.24B |
22.11% |
| 2010-06-30 |
$1.08B |
$0.24B |
22.68% |
| 2010-03-31 |
$1.05B |
$0.25B |
23.93% |
| 2009-12-31 |
$1.01B |
$0.24B |
23.86% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.347B |
$2.142B |
|
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
|
